Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Recent advances in cardioprotection during myocardial revascularization procedures: benefit of a metabolic intervention
Autore:
Danchin, N;
Indirizzi:
Hop Europeen Georges Pompidou, Dept Cardiol, F-75015 Paris, France Hop Europeen Georges Pompidou Paris France F-75015 F-75015 Paris, France
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: O, volume: 3, anno: 2001,
pagine: O21 - O25
SICI:
1520-765X(200111)3:O<O21:RAICDM>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSLUMINAL CORONARY ANGIOPLASTY; TRIMETAZIDINE; GLUCOSE; BYPASS; MULTICENTER; PROTECTION; SURGERY; ANGINA;
Keywords:
cariporide; coronary angioplasty; coronary bypass surgery; glucose-insulin-potassium; myocardial protection; trimetazidine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Danchin, N Hop Europeen Georges Pompidou, Dept Cardiol, 20 Rue Leblanc, F-75015 Paris, France Hop Europeen Georges Pompidou 20 Rue Leblanc Paris France F-75015
Citazione:
N. Danchin, "Recent advances in cardioprotection during myocardial revascularization procedures: benefit of a metabolic intervention", EUR H J SUP, 3(O), 2001, pp. O21-O25

Abstract

Among agents that can act directly on myocyte metabolism in order to ensure myocardial protection during revascularization procedures, trimetazidine is already available because of its anti-ischaemic properties in patients with angina pectoris. whereas others are still under investigation. In elective coronary angioplasty, trimetazidine delays ST-segment shift and reducesits extent by more than 40% during balloon inflation as compared with placebo. In the GUARD During Ischaemia Against Necrosis (GUARDIAN) trial, cariporide, an inhibitor of the sodium-hydrogen exchanger, had no effect on death or myocardial infarction. With regard to primary angioplasty for acute myocardial infarction, both the Limitation of Infarct Size by Trimetazidine (LIST) study and a trial that employed cariporide showed that metabolic intervention before angioplasty had favourable effects. Regarding coronary surgery, in the GUARDIAN trial, high-close cariporide was associated with fewercardiac events. Likewise, during coronary surgery, patients who were pretreated with trimetazidine exhibited lesser release of markers of myocardial injury. Therefore, metabolic intervention appears a Promising way to lessenmyocardial injury associated with revascularization procedures. Its long-term benefit, however, should be studied in large-scale therapeutic trials. (C) 2001 The European Society of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 21:58:49